CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting ...

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing. An fresh look at trial results that propelled the only FDA approval of a chimeric antigen ...

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are ...

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.

Companies are adopting diverse approaches to reducing unwanted toxicities associated with cell and gene therapy.

A newly discovered “energy switch” in the immune cells of the brain may lead to the development of drugs for Alzheimer’s disease, the most common form of dementia. Nanyang Technological University, ...

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

Water samples from 20 sites were tested using a panel of immortalized human cell lines corresponding to the liver, kidney and brain to measure cytotoxicity. Results show that each control toxin ...

Researchers at the Technion—Israel Institute of Technology Faculty of Biology have identified a unique mechanism involved in the aging of the immune system—along with a framework for enhancing its ...

Phase I clinical trial results suggest that an antibody treatment, used in combination with other drugs, enabled stem cell transplants for three children with Fanconi anemia without toxic busulfan ...